SOHM Inc (PK) (SHMN) Quote

You too hl, lots of time is right !

Cheers !

Good weekend all, Gin n tonics. (lots of lime) :)

do you know what truth even means ?

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173779054&txt2find=red%20flag

$SHMN:HL: I'd like to see these👇️guys '1' thro' '3' OWN some SHS!

***I have a feeling that the company is setting up a base for real investor interest in $SHMN
via some very REAL Business dealings with Companies [Incl Japanese Co's]
Surely after all this time it's NOT the same Old B.S. tweets?

I've talked about Dr. Bhatt in many of my posts earlier this year. He's well known & respected.
And apparently, he put his $ where his EXPERTISE is!

Why would they pass up an Opportunity like this?
Also:- S/Hs want to see what Barron's Stake is in $SHMN?

1. Mark Stevens, Science Advisor:

2. Eddie Chung, Coastar CEO:

3. Eric Furman, Ph.D. Knobbe Martens Sohm Intellectual Property Attorney:

4. Dr. Krishna Bhatt, Chief Medical Advisor, Bioscientist and Cardiologist:
Current owner of 82 Million Common shares, and recent Preferred Shares in exchange for Funding.

These are the Professionals at the $SHMN helm:

In no particular order...They can bring it home, imo.

Mark Stevens, Science Advisor:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174197635
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174136261
https://www.linkedin.com/in/mark-stevens-phd-810167a/

Eddie Chung, Coastar CEO:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174150084
"This marks a thrilling juncture for both companies and the realm of gene editing," stated Eddie Chung, CEO of Coastar. "We're intrigued by the precision and integrase capabilities presented by the ABBIE system. This partnership will yield a novel platform applicable in both laboratory and clinical use."
https://coastartherapeutics.com/about-us/
https://www.globenewswire.com/news-release/2024/04/01/2855240/0/en/SOHM-Inc-and-Coastar-Therapeutics-Sign-MoU-and-Announce-Collaboration-to-Revolutionize-Genome-Editing-Using-Red-Blood-Cell-Membrane-Derived-Carriers.html

Tony Tontat, Strategic Financial Analyst:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173733984
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173582848
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173546689

Alfred Gallegos, SHMN Research Scientist:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173660637
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173660026
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173659156
https://www.otcmarkets.com/stock/SHMN/news/SOHM-Collaborates-with-University-of-Arizona-Center-for-Innovation-to-Advance-ABBIE-a-Groundbreaking-Non-Viral-Gene-Edit?id=416912


Eric Furman, Ph.D. Knobbe Martens Sohm Intellectual Property Attorney:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173289185
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173246026

Wm. Dewey Rushing, VP of Quality Sohm:
https://www.linkedin.com/in/wm-dewey-rushing-7505a95/
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173082914
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173082680
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173031688
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172828177
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172794328
https://www.otcmarkets.com/stock/SHMN/news/SOHM-Inc-Announces-the-Appointment-of-Wm-Dewey-Rushing-as-VP-of-Quality-with-Immediate-Effect?id=413696
https://www.otcmarkets.com/stock/SHMN/news/SOHM-Inc-Announces-the-Appointment-of-Wm-Dewey-Rushing-former-US-FDA-Investigator-to-its-Advisory-Board?id=344969

Dr. Krishna Bhatt, Chief Medical Advisor, Bioscientist and Cardiologist:
Current owner of 82 Million Common shares, and recent Preferred Shares in exchange for Funding.
https://www.otcmarkets.com/otcapi/company/financial-report/396087/content
https://www.biomedwire.com/leadership-changes-at-sohm-inc-shmn-to-strengthen-growth-strategies-for-generic-drug-market-and-gene-editing-platform-development/
https://www.otcmarkets.com/stock/SHMN/news/SOHM-Inc-Expands-Its-Advisory-Board-Appointing-Dr-Krishna-Bhat-MD-PhD-FACC-as-Chief-Medical-Advisor?id=411792

Dr. David Aguilar, Sohm Chief Operating Officer:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172703663
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172599661
https://www.otcmarkets.com/stock/SHMN/news/SOHM-Inc-Announce-the-Appointment-of-Dr-David-Aguilar-PhD-as-a-Chief-Operating-Officer-with-the-Company-with-Immediate-E?id=410079
https://www.otcmarkets.com/stock/SHMN/news/SOHM-Inc-Expands-Advisory-Board-with-Appointment-of-Dr-David-Aguilar-PhD-as-its-Expert-Medical-Advisor?id=346149

We’re thrilled to announce that our presentation at #AACR was met with an exceptional reception. It was an honor to showcase our technology to esteemed researchers and leaders in the biotech industry.

The overwhelming interest and impact generated by our innovation have been… pic.twitter.com/50Ggv6hqPj— SOHM, Inc. (@sohminc) April 9, 2024

Join COO David Aguilar Ph.D., Research Scientist Alfred Gallegos, and Science Advisor Mark Stevens at #AARC2024 to discover our groundbreaking gene-editing platform that will revolutionize how we treat Colon Cancer.
More: https://t.co/tcmjjGEEW1#SOHMInc #ABBIE $SHMN pic.twitter.com/RzYwx8X4yy— SOHM, Inc. (@sohminc) March 28, 2024

After a successful visit to Japan, our COO, Dr. David Aguilar is back and here are couple pictures of him working at Carlsbad facility with production in-charge.

Secondly, we are glad to share that we are working with multiple companies for CDMO services and production at the… pic.twitter.com/Wj5qUGgpRe— SOHM, Inc. (@sohminc) January 25, 2024

Baron Night, CEO:
We are happy where things are today with the Year-end FDA approval of our Carlsbad manufacturing facility which will set our company up for a bright 2024 outlook.$SHMN pic.twitter.com/tehLBtiVNs— SOHM, Inc. (@sohminc) December 31, 2023


_____
More could be said, but I like the new SHMN. Baby Pharma at .0013.
hL

Well, the big difference is that stock is on the NASDAQ exchange and SHMN is an alternative reporting Pink Stock on the OTC.

Truth hurts.... cry a little more

4.63 billion market cap. $5.34 loss per share. $20 BV. Zero revenues. Impressive
https://finviz.com/quote.ashx?t=MDGL&p=d

SHMN needs to take lessons from them on how to pump up their stock cuz what they're doing isn't working.

I believe that is incorrect ". But unless it produces income, there will be no pps increase."

Notice the revenue and the stock price
https://www.otcmarkets.com/filing/html?id=17031890&guid=m4Q-ka3VoTeHJth

All on anticipation

Unfortunately, I think you're right, I just don't get these guys. The thing about abbie is that they can milk the hell out if it with tweets. But unless it produces income, there will be no pps increase. Penny stocks tend to run on mostly BS prs. Like acquisition, and such.
Or huge POs and sohm is making products that are already being made and are produced by reputable companies who are already established with distributors.

get over yourself clown.....

Shhhhh.... ABBIE is the new shiny object.... until the next one

Remember those two new production facility, do we ever hear any updates on those? If I had a big new fancy company producing medications, I would be proud and showing them off. Haven't heard a word recently.

Plus it seems like he can't read either.



drugmanrx

Re: MDPennyPlayer post# 65504

Thursday, April 18, 2024 9:27:22 AM
Post# of 65542
Reality, the pharmaceutical sales is not going to move this position very much until revenue reaches in the multi million dollar range.

I place my 3 plus million shares into a Roth because of Abbie.

If Abbie fly the stock flies.

With the pharmaceutical sales side actually looking like it is picking up the stock price should hold above these level going forward making it a very low risk to bet on Abbie success.


Sure looks like a bull statement rather then a bear.

Oh i know. They can't bash on any other board that i'm on or PM me since i have them blocked. Driving them nuts.... haha

That's impossible. I was just told that all bashers are worthless lowlife idiots.

Your right he has 3,850,000 shares

clown has 3 ml shrs......lol.....

all mouth..



I see your feeling are hurt and attacking me on the sn pw board

Grow up kid.

clown has 3 ml shrs......lol.....

all mouth...

here's a fact, we don't know if there were other suitors, but you claim there were none...that YOU have to prove clown..

I have proof of ONE SUITOR where your proof of others.

Well they owe 3 million in cash for it in about 8 months. They will have to sell alot of their non existant products to cover that.

ABBIE was acquired from CGA 369 for $10 million. The first payment of $6 million will be paid in 12 months from the effective date and will be a combination of $3 million cash and $3 million in restricted common stock.

that's the dumbest non answer I ever heard....

here's a fact, you have NO idea what co's offered to but ABBIE from Auguilar....period.

to say otherwise is a lie

Talk about proving a point... LOL

The lack of self awareness is pitiful

With Cash, Beginning of Period $7,264 , Cash, End of Period $116,016 (Period ending 9/30/23. ABBIE acquisition Sept 23. 2023) it is very hard to believe they would have been the higest bidder for ABBIE if anyone believed it had real value)

Unless Abbie was being offered for free.

BTW who was talking to you anyway!

I have proof of ONE SUITOR where your proof of others.

lol...not what I asked...hey, thanks for the 13's today !

Oh, you know what I'm currently invested in? LOLOLOLOL

What based on what's posted here? Please tell me you know there is a world outside of one stock forum....

your insults are ridiculous, just like that other company you bragged about here.....Solar Shit Panels...riight ?

reverse split right ?

money down the drain right ?

lol....

right, nice deflection......you know nothing about who offered to buy it and what they wanted to pay...period

lol....so why is SHMN the only co you bash, when most if not all of your pinky " plays " are worthless now....

I'll wait....

I'm sure SOHM was Aguilar's first choice to market ABBIE..... such a powerhouse in the field.... (end sarcasm)

Good luck trying to convince the know it all anything

do you know if SHMN was the only suitor ?

please, don't twist what I asked.....

it's a simple question, you said the only suitor, or were they the highest suitor ?

The person has issues.

Do you see ABBIE a part of any other company.

you say the only suitor, can you verify that ?

Prove i'm a paid basher, i'll wait..... You know nothing about me

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174227155

a nice civil conversation ?

lolol.....

I've heard better conversations at the Zoo.....

it's bashing 101, period. No one bashes a co for over 5 years that isn't being compensated....we all know that. If anyone in the World thinks a paid basher knows 2 shits about ABBIE I feel sorry for them.

Well we were having a nice civil conversation.... Board bullies can't stand others talking about the actual company. Only name calling

ABBIE can't be rushed, and those that call for fluff News would be the first to bitch about it.....

So far SHMN was at DCAT, then AACR, anyone that thinks a huge deal from either would be announced in days or weeks are bashing for cheaper shares, period.

hurry now, someone bring up the gummies !!!

LMAO !

funny you never mention this....

SOHM Collaborates with University of Arizona Center for Innovation to Advance ABBIE, a Groundbreaking Non-Viral Gene-Editing Technology

https://www.globenewswire.com/news-release/2023/10/10/2757629/0/en/SOHM-Collaborates-with-University-of-Arizona-Center-for-Innovation-to-Advance-ABBIE-a-Groundbreaking-Non-Viral-Gene-Editing-Technology.html

and this......lol..

who is going to market them

who are you trying to fool with this bullshit ?

Japan is emerging as a pioneer in the introduction of gene-edited foodstuffs. It allows gene-edited products to be sold to consumers without safety evaluations as long as the techniques involved meet certain criteria — a screening process similar to that adopted by the United States. It has introduced three CRISPR-edited products to date: fleshier red sea bream, high-growth tiger puffer, and a GABA-enriched tomato. Referred to in the media as a ‘super tomato’, it features five times the normal amount of GABA, an amino acid linked to lower blood pressure, thanks to tweaks to genes that normally limit GABA production.

https://crispr-gene-editing-regs-tracker.geneticliteracyproject.org/japan-crops-food/#:~:text=Japan%20is%20emerging%20as%20a,adopted%20by%20the%20United%20States.

you say the only suitor, can you verify that ?

SOHM, Inc.
@sohminc
We are pleased to share some photos of our Carlsbad plant with our valued customers who have requested them. Our operations are running smoothly and we are very satisfied with the results. We anticipate a strong performance in the first quarter. Thank you for your continued support and interest in our company.

2/5/2024

We are pleased to share some photos of our Carlsbad plant with our valued customers who have requested them. Our operations are running smoothly and we are very satisfied with the results. We anticipate a strong performance in the first quarter. Thank you for your continued… pic.twitter.com/oszy1uBCIB— SOHM, Inc. (@sohminc) February 5, 2024

why don't you ask the company, someone who might have a clue......

I'd pay to see a sit down between you and Dr Auguilar.......LMAO !

the basher smells blood in the water.....lol....

Without cas9 crispr gene therapy FDA approval for any use ABBIE also had no useful purpose. That's changed now and the door's wide open for approval for other treatments. ABBIE improves the accuracy and efficacy of those treatments, is my understanding.

December 8, 2023
Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY™ (Exagamglogene Autotemcel) for the Treatment of Sickle Cell Disease.

But I'm just a dumbass stock trader with an interest in medical science so what do I know.

You are way over thinking this.

Before Abbie came to SOHM , ABBIE was considered a failure(could be as simple as too far ahead of its time). Look how long it took Stem cells therapy to become common medical practice.

In 1958 the French oncologist, Georges Mathé, performed the first stem cell transplantation of bone marrow grafts to save six nuclear researchers who were accidentally exposed to radiation

But lucky for ABBIE technology and medical practices are forever evolving.

All ABBIE has to do is get the right partner with the right name attached to that partner and the stock price will explode, without the need to ever market a product themselves.

Agiluar is fishing in the right ponds and only needs one fish to bite.

At this state credibility is more important then marketing.

I kind of made that point earlier this month. Legitimate investors with deep pockets will not take an OTC company seriously. Especially one that has alternate reporting standards (unaudited).

If SHMN goes it alone, the "up to 5 mil" funding they got won't cut it. Have to assume, because it's unclear from the financials, that they are spending a majority of that on 2 manufacturing facilities.

The other part of ABBIE and the goods to be sold is who is going to market them. No one knows SOHM exists. How will they penetrate the market? Marketing is not cheap.

Appreciate the honest reply.

IMO! It is not a matter of money but a matter of getting the investing public to believe it has a legitimate future.

Currently the Abbie resume eight years of nothing and the only suitor is a sub penny stock.

Credibility of possible marketable very low.

How much capital do you think it will take for ABBIE to go from where it is today to where it needs to be to produce any appreciable money for SHMN?

To much story, not enough actual business happening

how and why is this so cheap it almost feels like its ready to blast needs more eyes on the story though pretty quiet on X out there